PresentationKyle Holen [Audio Gap] Some time with us. We're really excited about sharing with you some new data that we just shared earlier today on one of our assets, 4359 that's quickly becoming one of our newest late-stage assets similar to INT, which you've heard a lot about. I'm going to walk you through some of the INT data. And then we're just pleased to have some experts in the field that have joined us tonight to talk to you about melanoma and to talk to you about the data that was presented, the ...